CA2183551A1 - Vecteur de therapie genique pour le traitement de l'insuffisance ou des troubles de la production de globules rouges - Google Patents

Vecteur de therapie genique pour le traitement de l'insuffisance ou des troubles de la production de globules rouges

Info

Publication number
CA2183551A1
CA2183551A1 CA 2183551 CA2183551A CA2183551A1 CA 2183551 A1 CA2183551 A1 CA 2183551A1 CA 2183551 CA2183551 CA 2183551 CA 2183551 A CA2183551 A CA 2183551A CA 2183551 A1 CA2183551 A1 CA 2183551A1
Authority
CA
Canada
Prior art keywords
erythropoietin
control sequence
cells
muscle
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2183551
Other languages
English (en)
Inventor
Babru B. Samal
Yasuo Hamamori
Laurence H. Kedes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2183551A1 publication Critical patent/CA2183551A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne la thérapie génique pour améliorer la production de globules rouges. L'apport et l'expression du gène de l'érythropoïétine déclenchent une augmentation stable de la production de globules rouges. La présente invention traite également de vecteurs d'apport de recombinaison, de compositions, d'autres stratégies de thérapie génique, et de cellules transfectées qui expriment assez d'érythropoïétine pour présenter une réponse systémique physiologiquement significative.
CA 2183551 1993-11-10 1994-11-09 Vecteur de therapie genique pour le traitement de l'insuffisance ou des troubles de la production de globules rouges Abandoned CA2183551A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14987193A 1993-11-10 1993-11-10
US08/149,871 1993-11-10
US32048094A 1994-10-07 1994-10-07
US08/320,480 1994-10-07

Publications (1)

Publication Number Publication Date
CA2183551A1 true CA2183551A1 (fr) 1995-05-18

Family

ID=26847119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2183551 Abandoned CA2183551A1 (fr) 1993-11-10 1994-11-09 Vecteur de therapie genique pour le traitement de l'insuffisance ou des troubles de la production de globules rouges

Country Status (4)

Country Link
EP (1) EP0737252A1 (fr)
AU (1) AU1095595A (fr)
CA (1) CA2183551A1 (fr)
WO (1) WO1995013376A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
PT888385E (pt) 1996-03-14 2004-01-30 Genentech Inc Utilizacoes de gdnf e de receptores de gdnf
WO1998007878A2 (fr) * 1996-08-23 1998-02-26 Arch Development Corporation Expression prolongee de produits genetiques par transformation de cellules musculaires
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
EP1141313A2 (fr) 1998-12-31 2001-10-10 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
US6555343B1 (en) 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
EP1177285A1 (fr) * 1999-05-07 2002-02-06 Genentech, Inc. Nouveaux polypeptides d'erythropoietine du chimpanze (chepo) et acides nucleiques codant pour ces memes polypeptides
KR20030070702A (ko) * 2002-02-26 2003-09-02 사회복지법인삼성생명공익재단(삼성서울병원) 전기적 자극을 이용한 ｄｎａ 전달방법 및 이를 이용한 에리스로포이에틴 발현 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
JPH08501210A (ja) * 1992-07-02 1996-02-13 ザ ソールク インスチチュート フォア バイオロジカル スタディズ 遺伝子産物の持続的放出のための筋芽細胞の利用

Also Published As

Publication number Publication date
WO1995013376A1 (fr) 1995-05-18
AU1095595A (en) 1995-05-29
EP0737252A1 (fr) 1996-10-16

Similar Documents

Publication Publication Date Title
US5958769A (en) Compositions and methods for mediating cell cycle progression
Hamamori et al. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure.
US5656610A (en) Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US7053062B2 (en) Compositions and methods for inducing gene expression
US6670178B1 (en) In Vivo production and delivery of insulinotropin for gene therapy
CA2183551A1 (fr) Vecteur de therapie genique pour le traitement de l'insuffisance ou des troubles de la production de globules rouges
WO1997016533A1 (fr) Chromosomes mammaliens artificiels et procedes d'utilisation desdits chromosomes
WO1997047759A1 (fr) Vecteurs viraux adeno-associes recombines
Mao et al. STAT5 binding contributes to lactational stimulation of promoter III expressing the bovine acetyl-CoA carboxylase alpha-encoding gene in the mammary gland
EA008439B1 (ru) Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
BR112020007765A2 (pt) composições de vírus adeno-associados para restaurar a função do gene hbb e métodos de uso das mesmas
CN112639108A (zh) 治疗非综合征性感觉神经性听力损失的方法
TW200307749A (en) Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
Teshima-Kondo et al. Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site.
Petersen et al. Sustained production of human transferrin by transduced fibroblasts implanted into athymic mice: a model for somatic gene therapy
KR100267837B1 (ko) 화학요법제에 대한 감작성을 가진 억제유전자
AU737129B2 (en) Long-term expression of gene products by transforming muscle cells
MacColl et al. Optimisation of growth hormone production by muscle cells using plasmid DNA
CN113874512A (zh) 诱导毛细胞分化的组合物和方法
EP1305409B1 (fr) Elements de regulation renale et leurs procedes d'utilisation
KR970009159B1 (ko) 돼지 성장호르몬 동족체를 암호화하는 디엔에이
RU2686102C1 (ru) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
TWI260346B (en) Internal ribosome entry site of the labial gene for protein expression
KR20220049619A (ko) 유전자 발현 조절 시스템
JP4372684B2 (ja) 標的核酸への変異の導入方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead